摘要
目的 分析无偿献血者人类免疫缺陷病毒(HIV)与乙型肝炎病毒(HBV)、丙型肝炎病毒(HCV)以及梅毒螺旋体(TP)合并感染情况.方法 选取自2018年1月-2019年10月于广州市献血站无偿献血的献血者644706例作为研究对象,检测抗-TP、抗-HIV、抗-HCV及乙型肝炎表面抗原(HBsAg),统计和分析HIV与HBV、HCV及TP合并感染情况.结果 HBsAg阳性率为0.6%,抗-HIV阳性率为0.1%,抗-HCV阳性率为0.13%,抗-TP阳性率为0.26%.HIV合并HCV感染患者1例,感染率为0.15/万,HIV初筛阴性与阳性组感染率差异无统计学意义(P>0.05).HIV合并TP感染患者20例,感染率为0.31/万,HIV初筛阴性与阳性组感染率差异有统计学意义(P<0.05).HIV合并HBV感染患者1例,感染率为0.15/万,HIV初筛阴性与阳性组感染率差异有统计学意义(P<0.05).结论 无偿献血者HIV感染人群合并TP感染率较高,因此,为了为血液输血安全提供保障,必须提高输血前筛查质量,尽量将高危人群排除在外.
Objective To analyze the combined infection of human immunodeficiency virus(HIV) and hepatitis B virus(HBV), hepatitis C virus(HCV), and Treponema pallidum(TP) in unpaid blood donors. Methods A total of 644,706 blood donors who donated blood at the Guangzhou Blood Donation Station from January 2018 to October 2019 were selected as the research subjects. Detect and analyze HIV,HBV,HCV and TP co-infection. Results The HBsAg positive rate was 0.6%, the anti-HIV positive rate was 0.1%, the anti-HCV positive rate was 0.13%, and the anti-TP positive rate was 0.26%. One patient with HIV and HCV infection had an infection rate of 0.15/10 000. There was no significant difference in the infection rate between the negative and positive HIV screening groups(P>0.05). There were 20 HIV-infected patients with TP infection, and the infection rate was 0.31/10 000. There was a significant difference in the infection rates between the negative and positive HIV screening groups(P < 0.05). One patient with HIV and HBV infection had an infection rate of 0.15/10 000. There was a significant difference in the infection rate between the negative and positive HIV screening groups(P < 0.05). Conclusion Unpaid blood donors have a higher rate of TP infection in HIV-infected people. Therefore, in order to ensure the safety of blood transfusion, the quality of screening before blood transfusion must be improved and high-risk populations should be excluded as far as possible.
作者
蓝岚茵
郑剑婷
芦曦
王淏
LAN Lanyin;ZHENG Jianting;LU Xi;WANG Hao(Guangzhou Blood Center,Guangdong,Guangzhou 510095,China)
出处
《中国医药科学》
2020年第14期170-172,共3页
China Medicine And Pharmacy
基金
广东省医学科研基金立项项目(B2017109)。
